We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Screening Evaluation of the Evolution of New Heart Failure (SCREEN-HF)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00400257
First Posted: November 16, 2006
Last Update Posted: June 1, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
HBA
Information provided by (Responsible Party):
Ingrid Hopper, The Alfred
November 15, 2006
November 16, 2006
June 1, 2016
May 2007
January 2010   (Final data collection date for primary outcome measure)
To assess the effectiveness of BNP in determining Heart Failure in people not previously diagnosed with the condition. [ Time Frame: at visit 2 ]
Not Provided
Complete list of historical versions of study NCT00400257 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Screening Evaluation of the Evolution of New Heart Failure (SCREEN-HF)
SCREEN-HF (Screening Evaluation of the Evolution of New Heart Failure)
The investigators are hoping to identify early heart failure in patients who do not have symptoms as yet and at the same time assess the usefulness of Brain natriuretic peptide (BNP) in doing this.

Measuring Brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP)and can give us useful information about a persons heart function in patients with symptoms such as shortness of breath. This is because BNP/NT-proBNP levels rise when the heart is under pressure as it is in people with heart disease. However, we don't know if this is a useful test to do in people who are at a high risk of developing heart disease but who have no symptoms and have not been diagnosed with any heart problems.

In this study we hope to recruit 3500 participants. This study is being run in conjunction with HBA (recently renamed Bupa) and we estimate that 10,000 HBA members will need to be contacted by letter and invited to screen for this study to achieve the required 3500 (protocol amended to include people who meet the entry criteria but who are not insured through HBA).

This protocol has been amended to allow us to invite 50 participants with the lowest NT-proBNP levels to also continue in the study and have blood tests, an ECG and echocardiography as described below.

Participants will undergo a routine blood test which will include measuring NT-proBNP. Only participants in whom NT-proBNP is elevated will undergo additional blood tests (for cardiac markers), an ECG and echocardiography to determine if there is any indication that they do have heart disease even though they have not been diagnosed and are not symptomatic.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:
Blood samples
Non-Probability Sample
People at high risk of heart failure.
Heart Failure
Behavioral: Early detection of heart failure
Early detection of heart failure
1
People at high risk of heart failure.
Intervention: Behavioral: Early detection of heart failure
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
3500
December 2015
January 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Age ≥60 years
  2. Have been insured with HBA for 12 months or longer (Protocol amended to remove this criteria and allow enrollment of the general public)
  3. Subjects at high-risk of subsequent development of heart failure; comprising at least one of:

    • Prior myocardial infarction (MI) without known left ventricular (LV) dysfunction
    • Current active ischemic heart disease
    • Prior Cerebrovascular Accident (CVA)
    • Known valvular heart disease without known LV dysfunction
    • Atrial fibrillation
    • Ventricular arrhythmia resulting in syncope or pre-syncope (protocol amended to remove this entry criteria)
    • Treated hypertension, of at least 2 years duration
    • Treated Diabetes mellitus, of at least 2 years duration
    • Estimated Glomerular Filtration Rate (eGFR) <50ml/min

Exclusion Criteria:

  1. Known systolic or diastolic heart failure
  2. Symptoms suggestive of current heart failure. (protocol amended to remove this criteria)
  3. LV systolic or diastolic dysfunction on echocardiography or other objective imaging modality.
  4. Medications for treatment of heart failure such as ACE inhibitors, angiotensin receptor blockers (ARBs), beta-blockers or aldosterone antagonists. Use of such medications for approved indications such as hypertension, post-MI management (without known LV dysfunction) or for diabetic nephropathy is permitted. (protocol amended to remove this criteria)
Sexes Eligible for Study: All
60 Years and older   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
Australia
 
 
NCT00400257
CP-04/06
No
Not Provided
Not Provided
Ingrid Hopper, The Alfred
Ingrid Hopper
HBA
Principal Investigator: Henry Krum, Professor Monash University / Alfred Hospital
The Alfred
May 2016
To Top